Guidelines on the diagnosis and management of Waldenstrom macroglobulinaemia-A British Society for Haematology guideline was written by Pratt, Guy;El-Sharkawi, Dima;Kothari, Jaimal;D’Sa, Shirley;Auer, Rebecca;McCarthy, Helen;Krishna, Rajesh;Miles, Oliver;Kyriakou, Charalampia;Owen, Roger. And the article was included in British Journal of Haematology in 2022.Computed Properties of C16H21Cl2N3O2 The following contents are mentioned in the article:
A review. The objective of this guideline is to provide healthcare professionals with clear guidance on the management of patients with Waldenstrom macroglobulinemia. In individual patients, circumstances may dictate an alternative approach. This guideline was compiled according to the British Society for Haematol. (BSH) process at . Recommendations are based on a review of the literature using Medline, Pubmed, Embase, Central, Web of Science searches from beginning of 2013 (since the publication of the previous guidelines) up to Nov. 2021. The following search terms were used: Waldenstrom(‘s) macroglobulin(a)emia OR lymphoplasmacytic lymphoma, IgM(-related) neuropathy OR cold h(a)emagglutinin disease OR cold agglutinin disease OR cryoglobulin(a)emia AND (for group a only) cytogenetic OR mol. OR mutation OR MYD88 OR CXCR4, management OR treatment OR transfusion OR supportive care OR plasma exchange OR plasmapheresis OR chemotherapy OR bendamustine OR bortezomib OR ibrutinib OR fludarabine OR dexamethasone OR cyclophosphamide OR rituximab OR everolimus, bone marrow transplantation OR stem cell transplantation. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) nomenclature was used to evaluate levels of evidence and to assess the strength of recommendations. The GRADE criteria can be found at . Review of the manuscript was performed by the British Society for Haematol. (BSH) Guidelines Committee Haemato-Oncol. Task Force, the BSH Guidelines Committee and the Haemato-Oncol. sounding board of BSH. It was also on the members section of the BSH website for comment. It has also been reviewed by UK Charity WMUK; these organisations do not necessarily approve or endorse the contents. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Computed Properties of C16H21Cl2N3O2).
4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. Imidazole based anticancer drug find applications in cancer chemotherapy. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC).Computed Properties of C16H21Cl2N3O2
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem